Institutional & Family Asset Management’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $59.5K | Hold |
19,201
| – | – | 0.01% | 222 |
|
|
2024
Q1 | $87.2K | Sell |
19,201
-2
| -0% | -$9 | 0.01% | 197 |
|
|
2023
Q4 | $132K | Hold |
19,203
| – | – | 0.02% | 158 |
|
|
2023
Q3 | $121K | Hold |
19,203
| – | – | 0.02% | 161 |
|
|
2023
Q2 | $159K | Buy |
19,203
+4,226
| +28% | +$35.1K | 0.03% | 153 |
|
|
2023
Q1 | $65.9K | Hold |
14,977
| – | – | 0.01% | 201 |
|
|
2022
Q4 | $88.4K | Hold |
14,977
| – | – | 0.01% | 177 |
|
|
2022
Q3 | $105K | Buy |
14,977
+7,165
| +92% | +$50.2K | 0.02% | 165 |
|
|
2022
Q2 | $113K | Hold |
7,812
| – | – | 0.02% | 163 |
|
|
2022
Q1 | $294K | Hold |
7,812
| – | – | 0.05% | 130 |
|
|
2021
Q4 | $610K | Buy |
7,812
+7,312
| +1,462% | +$571K | 0.1% | 111 |
|
|
2021
Q3 | $50K | Buy |
+500
| New | +$50K | 0.01% | 323 |
|